The Valley Desk

ArticleCancersPublished

A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Cancers
Published
Subject terms
Ablation; prostate cancer; Clinical Trial; Focal Therapy; Irreversible Electroporation
PubMed ID
38927884
PubMed Central ID
PMC11201469
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal